Source: Annual Congress 2002 - COPD - general -2
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
A. Atasever, O. Kacmaz Basoglu, F. Bacakoglu (Izmir, Turkey). The efficacy of incentive spirometry in COPD patients. Eur Respir J 2002; 20: Suppl. 38, 1647

Member's Comments

No comment yet.

Related content which might interest you: Baseline characteristics of COPD patients with frequent COPD exacerbations in tiotropium trials Source: Eur Respir J 2006; 28: Suppl. 50, 175s Year: 2006 A realistic study assessing inhaled treatment compliance in COPD patients Source: Eur Respir J 2001; 18: Suppl. 33, 25s Year: 2001 Adherence to home spirometry among patients with IPF: results from the INMARK trial Source: International Congress 2019 – Biomarkers and beyond in idiopathic interstitial pneumonia Year: 2019 ArtiQ.QC facilitates spirometry quality control in asthma and COPD clinical trials Source: Virtual Congress 2021 – Future advances in respiratory physiology Year: 2021 Spirometry quality in patients with COPD Source: Annual Congress 2011 - Quality control in lung function and exercise-related issues Year: 2011 How the bronchodilatator in COPD patients works Source: Eur Respir J 2004; 24: Suppl. 48, 288s Year: 2004 Improvements in inspiratory capacity with tiotropium in patients with COPD Source: Eur Respir J 2002; 20: Suppl. 38, 491s Year: 2002 Dual bronchodilation with once-daily QVA149 improves lung function and reduces exacerbations in patients with COPD: The IGNITE trials Source: Annual Congress 2013 –New clinical trials of asthma and COPD drugs Year: 2013 Bronchodilator efficacy of tiotropium in patients with mild COPD Source: Eur Respir J 2006; 28: Suppl. 50, 616s Year: 2006 The effect of tiotropium in the treatment of patients with COPD Source: Annual Congress 2010 - COPD: management Year: 2010 Metronome-paced hyperventilation, CT measurements and exercise to investigate dynamic hyperinflation contrasting tiotropium versus indacaterol treatment in moderate COPD patients Source: International Congress 2015 – Unravelling the mechanisms of symptoms and exercise limitationas in disease Year: 2015 The effectiveness of procaterol on functional exercise capacity in COPD patients Source: Eur Respir J 2005; 26: Suppl. 49, 182s Year: 2005 QVA149 is more efficacious than tiotropium and salmeterol/fluticasone combination (SFC) in improving patient-reported outcomes and lung function in COPD patients with moderate-to-severe baseline dyspnoea: The IGNITE trials Source: International Congress 2015 – New data on established treatments for asthma, COPD and bronchiectasis Year: 2015 The effectiveness of pulmonary rehabilitation in elderly patients with COPD Source: Annual Congress 2004 - Outcome of pulmonary rehabilitation Year: 2004 Once-daily QVA149 demonstrates superior improvements in patient-reported dyspnea compared to tiotropium in patients with moderate-to-severe COPD: The BLAZE study Source: Annual Congress 2013 –Asthma and COPD management: novel clinical findings Year: 2013 Acute bronchodilator response does not predict health outcomes in patients with COPD treated with tiotropium Source: Annual Congress 2009 - Next generation bronchodilators Year: 2009 How can we improve availability of quality assured spirometry for patients admitted with an exacerbation of COPD? Source: Virtual Congress 2020 – Clinical and functional evaluation of COPD Year: 2020 Clinical and functional effectiveness of roflumilast in severe COPD patients Source: Annual Congress 2013 –Modern approach to various clinical settings Year: 2013 QVA149 improves lung function and reduces exacerbations compared to tiotropium in patients with severe-to-very severe COPD: The SPARK study Source: Annual Congress 2013 –Asthma and COPD management: novel clinical findings Year: 2013 The effectiveness of chest physiotherapy that is applied in COPD patients with exacerbation Source: Eur Respir J 2006; 28: Suppl. 50, 627s Year: 2006